Nucleo-mitochondrial asymmetry profiles the proliferative engine and spatial niche reconstruction in clear cell renal cell carcinoma - Summary - MDSpire

Nucleo-mitochondrial asymmetry profiles the proliferative engine and spatial niche reconstruction in clear cell renal cell carcinoma

  • By

  • Shansen Peng

  • Zhouzhou Xie

  • Ting Hu

  • Xia Li

  • Chunmei Yan

  • Chuyang Jiang

  • Huiming Jiang

  • Guihao Zhang

  • Nanhui Chen

  • June 12, 2026

  • 0 min

Share

Objective:

To investigate the role of nucleo-mitochondrial expression asymmetry (NMA) in tumor proliferation and spatial niche dynamics in clear cell renal cell carcinoma (ccRCC), highlighting its significance in disease progression.

Approach:
    Key Findings:
    • Identified a malignant subpopulation (C0) characterized by NMA, with decreased nucleo-mitochondrial coordination.
    • C0 exhibited the highest ribosomal activity, peak differentiation potential, and concentrated G2M/S-phase activity.
    • C0-dominant regions acted as metabolic hubs, correlating with total metabolic flux and accumulation of TCA cycle intermediates.
    • NMA-driven niches transitioned from an immune-active core to stroma-shielded metabolic islands as ccRCC progressed.
    • MT-CO1 protein levels positively correlated with the proliferation marker Ki67 and served as an independent prognostic factor for overall survival.
    Interpretation:

    NMA is characterized as a hallmark of ccRCC progression and spatial niche reconstruction, providing insights into tumor biology and potential clinical applications, particularly in treatment strategies.

    Limitations:
    • The study is limited to the specific cohort and methodologies employed, which may affect generalizability; further validation in larger, diverse populations is necessary to confirm findings.
    • Specific methodological concerns should be addressed to enhance the robustness of the conclusions drawn.
    Conclusion:

    NMA represents a critical aspect of ccRCC evolution, offering a novel framework for metabolic risk stratification via MT-CO1, with implications for future treatment strategies.

Original Source(s)

Related Content